A new phase 3 trial shows that DPP-1 inhibition with brensocatib reduces exacerbations and slows lung function decline in ...

Treatment with brensocatib also increased time to the first exacerbation and the proportion of patients remaining ...

For patients with bronchiectasis, brensocatib leads to a lower annualized rate of pulmonary exacerbations, according to a ...

including diagnostic criteria and management of acute exacerbation of CB (AECB) in the elderly patient.

Results show that compared with traditional treatments, HSK31858 significantly improves patient symptoms and reduces acute exacerbation frequency. This finding holds promise for bronchiectasis ...

Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo ...

In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 ...

Chronic bronchitis is a common disease in elderly patients. Acute exacerbation of chronic bronchitis (AECB) is a common feature of chronic obstructive pulmonary disease. Antibiotic therapy based ...